Fiche publication
Date publication
décembre 2017
Journal
European respiratory review : an official journal of the European Respiratory Society
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MASCAUX Céline
Tous les auteurs :
Mascaux C, Tomasini P, Greillier L, Barlesi F
Lien Pubmed
Résumé
After years of standard care prescribed to cancer patients without any selection except the primary site and histology of the tumour, the era of precision medicine has revolutionised cancer care. Personalised medicine refers to the selection of patients for specific treatment based on the presence of specific biomarkers which indicate sensitivity to corresponding targeted therapies and/or lower toxicity risk, such that patients will have the greatest chance of deriving benefit from the treatments. Here, we review personalised medicine for nonsmall cell lung cancer.
Mots clés
Antineoplastic Agents, adverse effects, Biomarkers, Tumor, genetics, Carcinoma, Non-Small-Cell Lung, drug therapy, Gene Rearrangement, Humans, Lung Neoplasms, drug therapy, Molecular Diagnostic Techniques, Molecular Targeted Therapy, Mutation, Precision Medicine, Risk Factors, Signal Transduction, drug effects
Référence
Eur Respir Rev. 2017 Dec 31;26(146):
